Current perspectives on FTY720

Bibliography

• PUGLIATTI M, ROSATI G, CARTON H et al.: The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. (2006) 13(7):700-722.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA K, TERASAKI PI: Annual trends and triple therapy – 1991 – 2000. Clin. Transpl. (2001):247-269.
   PubMed Web of Science ®Google Scholar
• JARDINE AG, FELLSTROM B, LOGAN JO et al.: Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study. Am. J. Kidney Dis. (2005) 46(3):529-536.
   PubMed Web of Science ®Google Scholar
• LENTINE KL, BRENNAN DC, SCHNITZLER MA: Incidence and predictors of myocardial infarction after kidney transplantation. J. Am. Soc. Nephrol. (2005) 16(2):496-506.
   PubMed Web of Science ®Google Scholar
• BUDDE K, SCHMOUDER RL, BRUNKHORST R et al.: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. (2002) 13(4):1073-1083.
   PubMed Web of Science ®Google Scholar
• SUZUKI S, ENOSAWA S, KAKEFUDA T et al.: A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation (1996) 61(2):200-205.
   PubMed Web of Science ®Google Scholar
• GOODIN DS, FROHMAN EM, GARMANY GP Jr et al.: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58(2):169-178.
   PubMed Web of Science ®Google Scholar
• CLEMENS JJ, DAVIS MD, LYNCH KR, MACDONALD TL: Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists. Bioorg. Med. Chem. Lett. (2005) 15(15):3568-3572.
   PubMed Web of Science ®Google Scholar
• KUNZENDORF U, ZIEGLER E, KABELITZ D: FTY720 – the first compound of a new promising class of immunosuppressive drugs. Nephrol. Dial. Transplant. (2004) 19(7):1677-1681.
   PubMed Web of Science ®Google Scholar
• PINSCHEWER DD, OCHSENBEIN AF, ODERMATT B et al.: FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. (2000) 164(11):5761-5770.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, DAVIS MD, HEISE CE et al.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. (2002) 277(24):21453-21457.
   PubMed Web of Science ®Google Scholar
• ZHANG H, DESAI NN, OLIVERA A et al.: Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J. Cell Biol. (1991) 114(1):155-167.
   PubMed Web of Science ®Google Scholar
• VOGLER R, SAUER B, KIM DS, SCHAFER-KORTING M, KLEUSER B: Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing. J. Invest. Dermatol. (2003) 120(4):693-700.
   PubMed Web of Science ®Google Scholar
• WANG F, NOHARA K, OLIVERA A, THOMPSON EW, SPIEGEL S: Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate. Exp. Cell Res. (1999) 247(1):17-28.
   PubMed Web of Science ®Google Scholar
• IM DS: Linking Chinese medicine and G-protein-coupled receptors. Trends Pharmacol. Sci. (2003) 24(1):2-4.
   PubMed Web of Science ®Google Scholar
• CHIBA K, YANAGAWA Y, MASUBUCHI Y et al.: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. (1998) 160(10):5037-5044.
   PubMed Web of Science ®Google Scholar
• YAGI H, KAMBA R, CHIBA K et al.: Immunosuppressant FTY720 inhibits thymocyte emigration. Eur. J. Immunol. (2000) 30(5):1435-1444.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, WILT C, KRISTOFIC C et al.: FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Transplant. Proc. (2001) 33(7-8):3078-3080.
   PubMed Web of Science ®Google Scholar
• BOHLER T, WAISER J, SCHUTZ M et al.: FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism. Transpl. Int. (2000) 13(Suppl. 1):S311-S313.
   PubMedGoogle Scholar
• AZUMA H, TAKAHARA S, ICHIMARU N et al.: Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. (2002) 62(5):1410-1419.
   PubMed Web of Science ®Google Scholar
• LAMONTAGNE K, LITTLEWOOD-EVANS A, SCHNELL C et al.: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. (2006) 66(1):221-231.
   PubMed Web of Science ®Google Scholar
• LEE TK, MAN K, HO JW et al.: FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res. (2005) 11(23):8458-8466.
   PubMed Web of Science ®Google Scholar
• SCHMID G, GUBA M, PAPYAN A et al.: FTY720 inhibits tumor growth and angiogenesis. Transplant. Proc. (2005) 37(1):110-111.
   PubMed Web of Science ®Google Scholar
• ZHOU C, LING MT, KIN-WAH LEE T et al.: FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. (2006) 233(1):36-47.
   PubMed Web of Science ®Google Scholar
• BILLICH A, BORNANCIN F, DEVAY P et al.: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. (2003) 278(48):47408-47415.
   PubMed Web of Science ®Google Scholar
• PAUGH SW, PAYNE SG, BARBOUR SE, MILSTIEN S, SPIEGEL S: The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. (2003) 554(1-2):189-193.
   PubMed Web of Science ®Google Scholar
• MATLOUBIAN M, LO CG, CINAMON G et al.: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 427(6972):355-360.
   PubMed Web of Science ®Google Scholar
• GRALER MH, GOETZL EJ: The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. (2004) 18(3):551-553.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, CYSTER JG, HLA T: FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. (2004) 4(7):1019-1025.
   PubMed Web of Science ®Google Scholar
• BOHLER T, BUDDE K, NEUMAYER HH, WAISER J: Novel mediators of FTY720 in human lymphocytes. Transplantation (2005) 79(4):492-495.
   PubMed Web of Science ®Google Scholar
• LEE MJ, THANGADA S, CLAFFEY KP et al.: Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 99(3):301-312.
   PubMed Web of Science ®Google Scholar
• TOLLE M, LEVKAU B, KEUL P et al.: Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res. (2005) 96(8):913-920.
   PubMed Web of Science ®Google Scholar
• BUDDE K, L SCHMOUDER R, NASHAN B et al.: Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am. J. Transplant. (2003) 3(7):846-854.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, KARLIX JL, FERGUSON RM et al.: Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, Phase I study. Transplantation (2003) 76(7):1079-1084.
   PubMed Web of Science ®Google Scholar
• YANAGAWA Y, MASUBUCHI Y, CHIBA K: FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. III. Increase in frequency of CD62L-positive T cells in Peyer’s patches by FTY720-induced lymphocyte homing. Immunology (1998) 95(4):591-594.
   PubMed Web of Science ®Google Scholar
• SKERJANEC A, TEDESCO H, NEUMAYER HH et al.: FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure–response relationship. J. Clin. Pharmacol. (2005) 45(11):1268-1278.
   PubMed Web of Science ®Google Scholar
• TEDESCO-SILVA H, MOURAD G, KAHAN BD et al.: FTY720, a novel immunomodulator: efficacy and safety results from the first Phase IIA study in de novo renal transplantation. Transplantation (2004) 77(12):1826-1833.
   PubMed Web of Science ®Google Scholar
• ROSEN H, GOETZL EJ: Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. (2005) 5(7):560-570.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, PINSCHEWER D, CHIBA K, FENG L: FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. (2000) 21(2):49-52.
   PubMed Web of Science ®Google Scholar
• HABICHT A, CLARKSON MR, YANG J et al.: Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J. Immunol. (2006) 176(1):36-42.
   PubMed Web of Science ®Google Scholar
• DRAGUN D, BOHLER T, NIEMINEN-KELHA M et al.: FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. Kidney Int. (2004) 65(3):1076-1083.
   PubMed Web of Science ®Google Scholar
• OJO AO, WOLFE RA, HELD PJ, PORT FK, SCHMOUDER RL: Delayed graft function: risk factors and implications for renal allograft survival. Transplantation (1997) 63(7):968-974.
   PubMed Web of Science ®Google Scholar
• ANSELMO D, AMERSI FF, SHEN XD et al.: FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury. Transplant. Proc. (2002) 34(5):1467-1468.
   PubMed Web of Science ®Google Scholar
• ANSELMO DM, AMERSI FF, SHEN XD et al.: FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am. J. Transplant. (2002) 2(9):843-849.
   PubMed Web of Science ®Google Scholar
• MAN K, NG KT, LEE TK et al.: FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am. J. Transplant. (2005) 5(1):40-49.
   PubMed Web of Science ®Google Scholar
• YAN SF, FUJITA T, LU J et al.: Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med. (2000) 6(12):1355-1361.
   PubMed Web of Science ®Google Scholar
• FUJISHIRO J, KUDOU S, IWAI S et al.: Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. Transplantation (2006) 82(6):804-812.
   PubMed Web of Science ®Google Scholar
• FUJISHIRO J, SUZUKI C, KUDOU S et al.: Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats. J. Heart Lung Transplant. (2006) 25(7):825-833.
   PubMed Web of Science ®Google Scholar
• SUZUKI C, TAKAHASHI M, MORIMOTO H et al.: Efficacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model. J. Heart Lung Transplant. (2006) 25(3):302-309.
   PubMed Web of Science ®Google Scholar
• LIEN YH, YONG KC, CHO C, IGARASHI S, LAI LW: S1P1-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. (2006) 69(9):1601-1608.
   PubMed Web of Science ®Google Scholar
• AKI FT, KAHAN BD: FTY720: a new kid on the block for transplant immunosuppression. Expert Opin. Biol. Ther. (2003) 3(4):665-681.
   PubMed Web of Science ®Google Scholar
• BRINKMANN V, LYNCH KR: FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. (2002) 14(5):569-575.
   PubMed Web of Science ®Google Scholar
• SUZUKI S, LI XK, SHINOMIYA T et al.: The in vivo induction of lymphocyte apoptosis in MRLlpr/lpr mice treated with FTY720. Clin. Exp. Immunol. (1997) 107(1):103-111.
   PubMed Web of Science ®Google Scholar
• OKAZAKI H, HIRATA D, KAMIMURA T et al.: Effects of FTY720 in MRLlpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J. Rheumatol. (2002) 29(4):707-716.
   PubMed Web of Science ®Google Scholar
• JEVNIKAR AM, GRUSBY MJ, GLIMCHER LH: Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J. Exp. Med. (1994) 179(4):1137-1143.
   PubMed Web of Science ®Google Scholar
• LUSTER AD, ALON R, VON ANDRIAN UH: Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. (2005) 6(12):1182-1190.
   PubMed Web of Science ®Google Scholar
• KARNI A, ABRAHAM M, MONSONEGO A et al.: Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. (2006) 177(6):4196-4202.
   PubMed Web of Science ®Google Scholar
• KATAOKA H, SUGAHARA K, SHIMANO K et al.: FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol. Immunol. (2005) 2(6):439-448.
   PubMed Web of Science ®Google Scholar
• FUJINO M, FUNESHIMA N, KITAZAWA Y et al.: Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. (2003) 305(1):70-77.
   PubMed Web of Science ®Google Scholar
• WEBB M, THAM CS, LIN FF et al.: Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. (2004) 153(1-2):108-121.
   PubMed Web of Science ®Google Scholar
• RE F, BELYANSKAYA SL, RIESE RJ et al.: Granulocyte-macrophage colony-stimulating factor induces an expression program in neonatal microglia that primes them for antigen presentation. J. Immunol. (2002) 169(5):2264-2273.
   PubMed Web of Science ®Google Scholar
• NOVGORODOV AS, EL-ALWANI M, BIELAWSKI J, OBEID LM, GUDZ TI: Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. (2007) (In Press).
   PubMedGoogle Scholar
• PETERS H, MARTINI S, WANG Y et al.: Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int. (2004) 66(4):1434-1443.
   PubMed Web of Science ®Google Scholar
• YOUNG BA, BURDMANN EA, JOHNSON RJ et al.: Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int. (1995) 48(2):431-438.
   PubMed Web of Science ®Google Scholar
• SHIHAB FS, ANDOH TF, TANNER AM et al.: Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int. (1996) 49(4):1141-1151.
   PubMed Web of Science ®Google Scholar
• YANG CW, AHN HJ, KIM WY et al.: Influence of the rennin–angiotensin system on epidermal growth factor expression in normal and cyclosporine-treated rat kidney. Kidney Int. (2001) 60(3):847-857.
   PubMed Web of Science ®Google Scholar
• KIM JY, LIM SW, LI C et al.: Effect of FTY720 on chronic cyclosporine nephropathy in rats. Transplantation (2005) 80(9):1323-1330.
   PubMed Web of Science ®Google Scholar
• XIN C, REN S, EBERHARDT W, PFEILSCHIFTER J, HUWILER A: The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br. J. Pharmacol. (2006) 147(2):164-174.
   PubMed Web of Science ®Google Scholar
• MANDALA S, HAJDU R, BERGSTROM J et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 296(5566):346-349.
   PubMed Web of Science ®Google Scholar
• HOJO M, MORIMOTO T, MALUCCIO M et al.: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 397(6719):530-534.
   PubMed Web of Science ®Google Scholar
• TANAKA T, TAKAHARA S, HATORI M et al.: A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett. (2002) 181(2):165-171.
   PubMed Web of Science ®Google Scholar
• AZUMA H, HORIE S, MUTO S et al.: Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anti-Cancer Res. (2003) 23(4):3183-3193.
   PubMed Web of Science ®Google Scholar
• NAGAHARA Y, IKEKITA M, SHINOMIYA T: T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br. J. Pharmacol. (2002) 137(7):953-962.
   PubMed Web of Science ®Google Scholar
• LIU Y, WADA R, YAMASHITA T et al.: Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. (2000) 106(8):951-961.
   PubMed Web of Science ®Google Scholar
• SCHMID G, GUBA M, ISCHENKO I et al.: The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J. Cell. Biochem. (2007) (In Press).
   Google Scholar
• CHUA CW, LEE DT, LING MT et al.: FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int. J. Cancer (2005) 117(6):1039-1048.
   PubMed Web of Science ®Google Scholar
• EASTON JB, HOUGHTON PJ: mTOR and cancer therapy. Oncogene (2006) 25(48):6436-6446.
   PubMed Web of Science ®Google Scholar
• ASSMANN G, GOTTO AM Jr: HDL cholesterol and protective factors in atherosclerosis. Circulation (2004) 109(23 Suppl. 1):III8-III14.
   PubMed Web of Science ®Google Scholar
• NOFER JR, VAN DER GIET M, TOLLE M et al.: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. (2004) 113(4):569-581.
   PubMed Web of Science ®Google Scholar
• NOFER JR, ASSMANN G: Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. (2005) 15(7):265-271.
   PubMed Web of Science ®Google Scholar
• KEUL P, TOLLE M, LUCKE S et al.: The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2007) 27(3):607-613.
   PubMed Web of Science ®Google Scholar
• NOFER JR, BOT M, BRODDE M et al.: FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2007) 115(4):501-508.
   PubMed Web of Science ®Google Scholar
• ZHOU X, PAULSSON G, STEMME S, HANSSON GK: Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. (1998) 101(8):1717-1725.
   PubMed Web of Science ®Google Scholar
• DORSAM G, GRAELER MH, SEROOGY C et al.: Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor. J. Immunol. (2003) 171(7):3500-3507.
   PubMed Web of Science ®Google Scholar
• JIN Y, KNUDSEN E, WANG L et al.: Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood (2003) 101(12):4909-4915.
   PubMed Web of Science ®Google Scholar
• WALTER DH, ROCHWALSKY U, REINHOLD J et al.: Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler. Thromb. Vasc. Biol. (2007) 27(2):275-282.
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis – an inflammatory disease. N. Engl. J. Med. (1999) 340(2):115-126.
   PubMed Web of Science ®Google Scholar
• MULGAONKAR S, TEDESCO H, OPPENHEIMER F et al.: FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am. J. Transplant. (2006) 6(8):1848-1857.
   PubMed Web of Science ®Google Scholar
• SALVADORI M, BUDDE K, CHARPENTIER B et al.: FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant. (2006) 6(12):2912-2921.
   PubMed Web of Science ®Google Scholar
• TEDESCO-SILVA H, PESCOVITZ MD, CIBRIK D et al.: Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation (2006) 82(12):1689-1697.
   PubMed Web of Science ®Google Scholar
• GALETTA SL, MARKOWITZ C: US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs (2005) 19(3):239-252.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, ANTEL J, COMI G et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355(11):1124-1140.
   PubMed Web of Science ®Google Scholar